Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry

Abstract

In recent years, more intensive chemotherapy regimens for mantle cell lymphoma (MCL) have been associated with prolongation of survival. In this study, our aim was to investigate prognostic factors and evaluate improvement in survival in MCL on a population level. The cohort included all patients diagnosed with MCL from 1 January 2000 to 31 March 2010 in the Swedish Lymphoma Registry. At total of 785 patients with MCL were identified. Age, performance status, and B-symptoms were significant prognostic factors for overall survival (OS) in multivariate analysis. In addition, OS was markedly improved (hazard ratio 0.8, 95% confidence interval 0.7–0.9) for patients diagnosed during the latest time period, 2006–2010, also when corrected for prognostic factors as above. Estimated OS at 3 years was 62%, compared to 47% for patients diagnosed earlier (p < 0.01). The reasons for this dramatic improvement in OS are not yet clear, but may be due to the introduction of specific and more potent therapeutic regimens.

Keywords:

• Mantle cell lymphoma
• population
• Swedish Lymphoma Registry

Acknowledgements

We would like to express our gratitude to Oskar Hagberg, statistician, Department of Tumor Epidemiology, Lund, Sweden, for extracting data from the Swedish Lymphoma Registry and the Population Registry, and to all clinicians reporting data to the registry.

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.